|1.||Selvendiran, Karuppaiyah: 10 articles (10/2014 - 06/2009)|
|2.||Kuppusamy, Periannan: 10 articles (10/2014 - 06/2009)|
|3.||Hideg, Kálmán: 9 articles (04/2014 - 06/2009)|
|4.||Rivera, Brian K: 7 articles (04/2014 - 06/2009)|
|5.||Kuppusamy, M Lakshmi: 7 articles (11/2011 - 06/2009)|
|6.||Kálai, Tamás: 7 articles (11/2011 - 06/2009)|
|7.||Dayton, Alex: 5 articles (11/2011 - 05/2010)|
|8.||Ahmed, Shabnam: 4 articles (11/2011 - 05/2010)|
|9.||Bratasz, Anna: 4 articles (09/2010 - 06/2009)|
|10.||Tierney, Brent J: 3 articles (10/2014 - 07/2012)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2010 - "The study suggested that HO-3867 may be useful as a safe and effective anticancer agent for ovarian cancer therapy."
11/01/2011 - "The results, combined with the previously-reported safety features of HO-3867, suggest the potential use of this compound as a safe and effective adjuvant for the treatment of ovarian cancer."
09/01/2010 - "The study suggests that molecular targeting of FAS and FAK by HO-3867 may be a potential strategy for ovarian cancer therapy."
04/15/2014 - "HO-3867 exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in ovarian cancer cells. "
04/15/2014 - "HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer."
11/01/2011 - "The study indicates that combination treatment of HO-3867 and DOX is a viable option for treatment of cancer with reduced cardiotoxic side effects."
10/01/2014 - "HO-3867 mediated a dosage-dependent inhibition of the growth of xenografted endometrial tumors. "
04/15/2014 - "The selective cytotoxicity of HO-3867 seemed to be multifaceted, eliciting differential activation of the Akt pathway in normal versus cancer cells. "
11/01/2011 - "This work investigated the use of HO-3867 and DOX to achieve a complementary outcome, i.e., increased toxicity toward cancer cells, and reduced cardiac toxicity. "
11/15/2010 - "HO-3867 was substantially cytotoxic to all the cancer cells tested. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
10/01/2014 - "HO-3867 treatment decreases the high levels of pSTAT3 Ser727 in endometrial cancer cells by inducing cell cycle arrest and apoptosis. "
10/01/2014 - "Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor."
10/01/2014 - "In the present study, we examine the expression of STAT family of proteins in endometrial cancer cell lines and the efficacy of HO-3867, a novel STAT3 inhibitor designed in our lab. "
11/01/2011 - "HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition."
09/01/2010 - "HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase."
|5.||Osteosarcoma (Osteogenic Sarcoma)
10/01/2015 - "In addition, knockdown of LIF notably suppressed the proliferation and invasion of osteosarcoma via blocking the STAT3 signal pathway; in contrast, treatment with the recombinant LIF protein significantly promoted the growth and invasion of osteosarcoma through enhancing the phosphorylation of STAT3, which can be partially neutralized by the STAT3 inhibitor, HO-3867. "
|1.||Proteins (Proteins, Gene)
|4.||Sterol Regulatory Element Binding Protein 1
|5.||Mitogen-Activated Protein Kinase 3
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Matrix Metalloproteinase 2 (Gelatinase A)
|8.||Messenger RNA (mRNA)
|9.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)